A Public Health and Budget IMPACT Analysis (BIA) of Vaccinating Adults of Risk Groups Against Pneumococcal-Diseases in Austria

Author(s)

Walter E, Voit M, Eichhober G
Institute for Pharmaeconomic Research, Vienna, Austria

OBJECTIVES : Pneumococcal-disease in adults, including community-acquired-pneumonia (CAP) and invasive-pneumococcal-disease (IPD), is a global problem, especially in individuals with chronic-diseases such as COPD, diabetes-mellitus (DM) and chronic-heart-disease (CHD). A vaccination recommendation for these populations exists (aged ≥50) in Austria. A sequential vaccination, PNC13 and after ≥8 weeks PPV23, is strongly recommended. This sequential vaccination should be repeated every 6 years. The aim of the BIA is to compare the current situation with a higher vaccination-coverage scenario. The budget-impact quantifies the effect due to vaccination regarding health-care budget and events avoided.

METHODS : A multi-cohort, population-based model was developed over a 5-year time-horizon for each risk-group (COPD, DM, CHD; ≥50 years). The following states were included: hospitalized/outpatient CAPs, IPDs, associated complications and mortality. The current vaccination-rate is 14% (1st year) to 22% (5th year). After the market shift, a vaccination-rate of 60% is assumed. The model includes a serotype shift over time. Results showed savings form the health-care-systems perspective and prevented events (CAPs, IPDs and deaths).

RESULTS : In COPD patients (N=94,885; GOLD III) an increased vaccination-rate results in total savings of 41.6 million € (m€) over 5 years; between 5.8 m€ (1st year) to 11.2 m€ (5th year). In total 8,967 CAPs, 343 IPDs and 753 deaths could be avoided. A higher vaccination-rate in the DM population (N=340,890) leaded in total savings of 21.3 m€ over 5 years; 4.0 m€ (1st year) to 4.6 m€ (5th year). Savings are associated with 8,852 prevented CAPs, 174 IPDs and 531 deaths in a 5 year time horizon. In the CHD risk-group (N= 280,163) saving of 27.2 m€ could be achieved in total; 5.5 m€ (1st year) to 5.9 m€ (5th year). 7,974 CAPs, 189 IPDs and 704 deaths could be avoided.

CONCLUSIONS : In Austria, 1€ invested in pneumococcal vaccination obtained a return-on-investment between 2 and 13.3€ for the health-care-system.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PIN15

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Vaccines

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×